Eli Lilly 3Q Revenue Climbs on Demand for Mounjaro, Zepbound
By Kelly Cloonan
Eli Lilly's quarterly revenue jumped on growing demand for its diabetes and obesity drugs Mounjaro and Zepbound.
The results prompted the pharmaceutical company to raise its revenue guidance for the full year.
Third-quarter profit came in at $6.45 billion, or $7.22 a share, compared with $5.58 billion, or $6.21 a share, a year earlier.
Adjusted earnings per share were $7.48, compared with analyst estimates of $5.68, according to FactSet.
Revenue climbed 39% to $24.4 billion, compared with analyst estimates of $22.58 billion.
Surging demand for Lilly's diabetes and obesity drugs continued to drive much of its growth. Sales for Mounjaro increased 65% to $10.72 billion, while Zepbound sales rose 49% to $5.35 billion.
For the full year, Lilly now expects revenue between $91 billion to $92 billion, up from a prior view of $85 billion to $87 billion.
The company also updated its profit guidance to factor in acquired in-process research-and-development charges, now forecasting adjusted earnings per share of $35 to $36, compared with $35.50 to $36.50 previously.
Shares rose 3.3%, to $1,331, in premarket trading.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
October 29, 2026 07:26 ET (11:26 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
What 7 Key Market Indicators Are Telling Investors Right Now
United States